The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.00
Bid: 18.90
Ask: 19.98
Change: -0.50 (-2.56%)
Spread: 1.08 (5.714%)
Open: 20.00
High: 20.00
Low: 19.00
Prev. Close: 19.50
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

20 Apr 2017 07:00

RNS Number : 7890C
Nanoco Group PLC
20 April 2017
 

Nanoco Group plc

("Nanoco" or the "Company")

 

Directorate Change

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, is pleased to announce the appointment of Dr Alison Fielding as a Non-executive Director with effect from 20 April 2017.

 

Alison is Director of Strategy and IP Impact at IP Group and is currently a Non-executive Director of Getech Group plc. She holds an MBA from Manchester Business School, a PhD in organic chemistry and a first-class degree in chemistry from the University of Glasgow. Alison started her career at Zeneca PLC (now Astra Zeneca) followed by five years at McKinsey & Company and later co-founded Techtran Group Limited which was acquired by IP Group in 2005 where she held the role of director and COO until 2013. Whilst at IP Group, she also sat on the board of and advised several early stage and quoted IP Group backed technology companies.

 

Alison's appointment follows the announcement in January that Robin Williams would stand down as a Non-executive Director in July due to other commitments. Alison will succeed Robin as Chair of the Audit Committee on 13 July 2017. She will also be a member of the Remuneration Committee.

 

Dr Christopher Richards, Nanoco's Chairman, said: "Alison brings an exceptional breadth of relevant skills to the Nanoco Board, with her background in chemistry and her extensive commercial, financial and international experience across the technology sector. Her appointment will strengthen the Board significantly as we move forward to commercial success and her extensive Board experience will also reinforce Nanoco's continued commitment to governance."

 

Alison has been a director of several publicly quoted companies, including Fusion IP plc, hVIVO plc, IP Group plc and Tissue Regenix Group plc.

 

The Company confirms that there is no additional information which is required to be disclosed under Rule 9.6.13 of the Listing Rules of the UK Listing Authority.

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

David Blain, Chief Financial Officer

Caroline Watson, Investor Relations Manager

Tel: + 44 (0) 7799 897357

cwatson@nanocotechnologies.com

 

Peel Hunt

 

Tel: +44 (0) 20 7418 8900

Adrian Trimmings

George Sellar

Alex Lomax

MHP Communications

Tel: +44 (0) 20 3128 8100

Reg Hoare / Andrew Leach / Giles Robinson / Peter Lambie

Nanoco@mhpc.com

 

About Nanoco Group plc

 

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, Nanoco has non-exclusive manufacturing and marketing licensing agreements with The Dow Chemical Company, Merck KGaA and Taiwan's Wah Hong Industrial Corporation. Nanoco also has a strategy of direct sales in display and in its other target markets, including lighting.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFLDSTIALID
Date   Source Headline
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding
16th Aug 20227:00 amRNSTrading Update
28th Jul 202210:42 amRNSHolding(s) in Company
13th Jul 20222:03 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.